Skip to main content

Advertisement

Radiation therapy for vaginal cancer in complete uterine prolapse with intrauterine adhesion: a case report

Article metrics

  • 625 Accesses

Abstract

Background

We encountered a woman with vaginal cancer that was associated with complete uterine prolapse and complicated by severe intrauterine adhesions. In this case report, we describe the clinical course and successful treatment of this rare condition.

Case presentation

A 78-year-old woman (gravida 10, para 2, abortion 8) with a 10-year history of uterine prolapse presented for evaluation of bleeding from an ulceration on the surface of the irreducibly prolapsed uterus. Biopsy of a mass on her vaginal wall led to a diagnosis of keratinizing squamous cell carcinoma. Her history of eight abortion procedures had resulted in severe intrauterine adhesions, preventing tandem insertion and intracavitary brachytherapy. She was also ineligible for surgery under general anesthesia + chemotherapy because of her advanced age and presence of arrhythmia. Therefore, we devised an extensive treatment plan involving high-dose-rate interstitial brachytherapy. This treatment successfully eliminated the squamous cell carcinoma as confirmed by biopsy with no recurrence or severe late complications.

Conclusions

We found that high-dose-rate interstitial brachytherapy may be a very effective therapeutic strategy for this condition with few adverse effects.

Background

Among various types of pelvic organ prolapse, uterine prolapse is occasionally observed in parous women and women of advanced age. When mild cases of uterine prolapse are included, the incidence is reported to range widely from 2.9 to 93.6% among women in the general population [1,2,3]. The literature contains sporadic reports of uterine cervical cancer in women with uterine prolapse [4,5,6,7]. The standard treatment options for medically inoperable uterine cervical cancer are pelvic external beam radiation therapy (EBRT) and brachytherapy (BT). We encountered a woman of advanced age with vaginal cancer associated with complete uterine prolapse, for which BT was planned. The patient had a history of several abortion procedures, and the resultant severe intrauterine adhesions prevented insertion of the tandem. Therefore, we planned high-dose-rate (HDR) interstitial BT (ISBT), in which plastic needles were directly inserted under direct visual observation to surround the margin of the ulcerated lesion of the vaginal cancer associated with complete uterine prolapse. After insertion of the plastic BT needles, dummy sources were inserted and computed tomography (CT) was performed. Using a treatment planning system, dose–volume histogram analysis was performed to develop a plan for covering the lesion, and HDR ISBT was administered. Very few reports have described detailed irradiation procedures for radiation therapy (RT) in the treatment of vaginal or uterine cervical cancer associated with uterine prolapse [8,9,10]. Furthermore, this is the first reported case of this condition complicated by intrauterine adhesions.

Case presentation

A 78-year-old Japanese woman (gravida 10, para 2, abortion 8) had a 10-year history of uterine prolapse but she had no gynecological examination. She had no smoking history and her body mass index was 19.7. She visited our hospital because of a 1-month history of bleeding from an ulcerated lesion on the surface of the prolapsed uterus. Upon examination, the uterine prolapse appeared as complete eversion of the posterior vaginal fornix and was manually irreducible and classified as stage IV according to the Pelvic Organ Prolapse Quantification System [11]. On the surface of the completely prolapsed uterus, an ulcerated lesion of 3 cm in diameter was observed and a deep-seated induration was felt. A histological biopsy of a mass in the vaginal wall led to a diagnosis of keratinizing squamous cell carcinoma. Magnetic resonance imaging revealed the mass with a depth of 1.6 cm, but the endometrial cavity was not depicted (Fig. 1). The mass was located approximately 3 cm from the cervical os with no sign of invasion to adjacent tissue. According to the International Federation of Gynecology and Obstetrics (FIGO) staging system, the tumor was vaginal cancer staged as I, and a fluorodeoxyglucose positron emission tomography/CT revealed no metastases to the lymph nodes or other organs. Although the diagnosis of this case was vaginal cancer, the main tumor was located in the uterine cervix because of the completely prolapsed uterus. Therefore, we considered that it is practical to develop the treatment plan according to the uterine cervical cancer. Because of the patient’s advanced age and the presence of arrhythmia (paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation), she was ineligible for a combination of surgery under general anesthesia and chemotherapy; therefore, RT alone was planned. If EBRT had been administered, radiation dermatitis of the genitalia would have been a concern because the prolapsed uterus would be irradiated. Neither a probe nor a tandem could be inserted because of severe intrauterine adhesions due to her history of multiple abortion procedures, also known as Asherman syndrome [12, 13]. The cervical canal was extremely narrowing due to advanced age. Thus, intracavitary BT (ICBT) could not be administered. In addition, the complete uterine prolapse inhibited fixation of an ovoid tandem to the vaginal fornices. Thus, ISBT was planned, in which plastic needles would be directly inserted into the margin of the ulcerated lesion on the surface of the completely prolapsed uterus under direct visual observation. In the BT treatment room, four plastic BT needles (LLA150-K; Eckert & Ziegler BEBIG, Berlin, Germany) were inserted into the margin of the ulcerated lesion to a depth of up to 3 cm under local anesthesia to sufficiently cover the lesion, the depth of which was 1.6 cm as previously measured by magnetic resonance imaging (Fig. 2). Under only local anesthesia, direct insertion of the plastic BT needles caused very little pain. Next, a dummy source for X-ray imaging (LLH02–21 to 24) was inserted into the lumen of each of the four plastic BT needles, and X-ray imaging was performed. The patient was then transferred to the CT room. CT was performed with 2-mm slices, confirming that the BT sources had been inserted around the lesion (Fig. 3). At our facility, HDR ISBT is administered using a 60Co remote afterloading system (RALS) (MultiSource; Eckert & Ziegler BEBIG). Thus, these CT scans were uploaded to the RALS treatment planning system (HDR plus; Eckert & Ziegler BEBIG). According to the guidelines established by the Groupe Europeen de Curietherapie and European Society for Radiotherapy and Oncology [14, 15], the gross tumor volume (GTV) and organs at risk (OARs) (i.e., the rectum and bladder) were contoured. The high-risk clinical target volume (HR-CTV) including the whole cervix could not be contoured because the endometrial cavity was not depicted and the whole extent of the cervix was not defined. The GTV was 19.4 cc, and treatment was planned with a dose of ≥6 Gy prescribed as D90 of the GTV (minimum dose delivered to 90% of the GTV) (Fig. 4). On another day, the plastic BT needles and dummy sources were reinserted, and X-ray imaging was performed, followed by CT. A similar treatment plan was developed. At our facility, X-ray films alone are used to check the location of radiation sources for BT and develop treatment plans. In this case, X-ray films were obtained after insertion of each plastic BT needle and the dummy sources, and two treatment plans were developed (Table 1). We selected the plan with the dummy sources placed closer to the lesion, according to which HDR ISBT was administered at 6 Gy per fraction twice weekly for a total of eight times. When the location of the dummy sources deviated from the planned sites, the plastic BT needles were reinserted to ensure administration based on one of the treatment plans. The total accumulation dose of HDR ISBT was estimated to be 65.0 Gy as D90 of the GTV (equivalent dose in 2-Gy fractions [EQD2]). One month after the completion of RT, the histological biopsy revealed remaining squamous cell carcinoma. Therefore, we performed additional HDR ISBT at 6 Gy per fraction twice weekly for a total of six times until the ulcerated lesion became soft and flat. The final total accumulation dose of HDR ISBT was estimated to be 113.8 Gy as D90 of the GTV (EQD2), 20.7 Gy as D2cm3 of the rectum (EQD2), 36.8 Gy as D2cm3 of the bladder (EQD2) with α/β = 10 for the GTV and α/β = 3 for the OARs (Table 1). Because of the complete uterine prolapse, the GTV was remote from the rectum and bladder; therefore, the exposure doses to the OARs were extremely low. The only observed acute complication was grade 2 dermatitis in the genitalia (National Cancer Institute Common Terminology Criteria for Adverse Events of 4.03 [16]). One month after the completion of additional HDR ISBT, no residual squamous cell carcinoma was detected in the tissue biopsy. Two months after additional HDR ISBT, as late toxicities, local ulcer lesion with fibrositis was seen in the labium majus and tumor bed in the vaginal wall, and debridement was performed. Three months after additional HDR ISBT, no recurrence or rectal and urinary toxicity had occurred.

Fig. 1
figure1

T2-weighted magnetic resonance imaging in the sagittal plane showing a stage IV completely prolapsed uterus defined as eversion of the total length of the lower genital tract. The external cervical os (white arrows) was observed, but no endometrial cavity was detected

Fig. 2
figure2

Vaginal cancer with an ulcer in the uterine prolapse (stage IV in the Pelvic Organ Prolapse Quantification System). Four plastic needles were implanted around the ulcer (white arrows)

Fig. 3
figure3

Axial computed tomography scan demonstrating four interstitially implanted dummy sources (white arrows)

Fig. 4
figure4

a Axial and b sagittal computed tomography scans with high-dose-rate interstitial brachytherapy dosimetry from 10- to 3-Gy isodose lines. The the gross tumor volume (red dotted line) was well covered by the prescribed 6-Gy isodose line. The rectum (green dotted line) and bladder (yellow dotted line) are only slightly irradiated

Table 1 Dose–volume histogram for the gross tumor volume and organs at risk at a prescribed dose of 6 Gy per fraction and the total accumulation dose

Discussion and conclusions

Although uterine cervical cancer occurring in patients with uterine prolapse has been sporadically reported to date, the incidence rate of this condition is unknown. Based on the information we obtained, the rate is estimated to range from 0.14 to 1.00% [4, 7]. Moreover, no standard treatment for uterine cervical cancer occurring in women with uterine prolapse has been established. Whether this condition should be treated with surgery-based or RT-based therapy remains to be determined [7, 17]. The detailed irradiation procedures used for RT administered for uterine cervical cancer associated with uterine prolapse have been reported in only three cases [8,9,10] (Table 2), and this is the first reported vaginal cancer of this condition complicated by intrauterine adhesions. Among these previous cases, EBRT alone was administered in one case and a combination of EBRT and ICBT was applied in the other two. Uterine prolapse was spontaneously reduced before EBRT in one case, and reduction was achieved by pessary use and perineoplasty before EBRT in another case [8, 10]. In the third case, the uterine prolapse could not be reduced before EBRT, and radiation cystitis also occurred [9]. When EBRT is administered, reduction of uterine prolapse and hysterectomy are recommended before EBRT to reduce the risks of visceral injury and vesicovaginal or rectovaginal fistulas of the surrounding organs [18, 19]. When BT is administered, however, the exposure doses to the rectum and bladder can be reduced when the uterus remains prolapsed. In fact, the exposure doses delivered to the OARs by HDR ISBT were very low in our case. The standard procedure of RT for uterine cervical cancer is generally a combination of EBRT and ICBT [20]. According to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Cervical Cancer, BT alone is an option for very early disease, and ISBT is selected in rare cases in which ICBT is not feasible depending on the anatomy or tumor geometry [20]. Furthermore, the American Brachytherapy Society recommends ISBT for cases involving a bulky lesion, a narrow vagina, the inability to enter the cervical os, extension to the lateral parametrium or pelvic side wall, and lower vaginal extension [21]. ISBT was administered in our case because severe intrauterine adhesions inhibited ICBT. HDR ISBT is a therapeutic procedure performed by inserting 5 to 30 needle applicators from the perineum to the cervical cancer under general or spinal anesthesia. This procedure is often combined with ICBT and performed during the later stage or after completion of whole-pelvis EBRT [22,23,24]. In the present case, we needed to plan RT with the lowest possible toxicity because of her advanced age and arrhythmia; therefore, only HDR ISBT was administered. Thus, neither gastrointestinal nor genitourinary toxicity was observed. Moreover, under local anesthesia only without the need for general or spinal anesthesia, direct insertion of plastic BT needles to the prolapsed uterus caused very little pain. No optimal dose of HDR ISBT for uterine cervical cancer has been determined. However, based on previous reports, the optimal dose per fraction ranges from 4 to 7 Gy for HDR ISBT, and the optimal total D90 for HR-CTV (EQD2) ranges from 67.6 to 96.6 Gy when HDR ICBT and EBRT are combined [23,24,25]. In one study, when stage ≥T3a tumors with a median HR-CTV of 29.8 cc were treated with a total D90 for HR-CTV (EQD2) of 80.6 Gy, the local control rate was 83% [23]. In another study, when FIGO stage ≥IIB tumors with a median HR-CTV of 103 cc were treated with a D90 for HR-CTV (EQD2) of 67.6 Gy, the local control rate was 80% [24]. Furthermore, when relatively small tumors measuring 2 to 5 cm were treated with a D90 for HR-CTV (EQD2) of 89 Gy, the local control rate was 96.9% [25]. Finally, when small tumors measuring ≤4 cm were treated with a total D90 for HR-CTV (EQD2) of 69.0 Gy, the local control rate was 96% [26]. In our case, the GTV was 19.4 cc, which is smaller than the HR-CTV described in previous reports. In the first treatment, we treated the total D90 for GTV (EQD2) of 65.0 Gy appeared sufficient compared with these previous reports, but biopsy revealed residual squamous cell carcinoma. This first treatment dose may be insufficient if chemotherapy was not performed. We could add HDR ISBT with observation of the treatment effect by biopsy, and the total D90 for GTV (EQD2) of 113.8 Gy appeared sufficient. No residual squamous cell carcinoma was detected after completion of the additional HDR ISBT. This additional procedure is advantageous over EBRT. The limitation of our case is the short follow-up period. When vaginal or uterine cervical cancer develops in women with uterine prolapse and intrauterine adhesions, HDR ISBT may be an effective therapeutic strategy with less adverse effects compared with EBRT.

Table 2 Cases of cervical/vaginal cancer in patients with uterine prolapse treated by radiation therapy

Abbreviations

BT:

Brachytherapy

CT:

Computed tomography

EBRT:

External beam radiation therapy

EQD2:

Equivalent dose in 2-Gy fractions

FIGO:

International Federation of Gynecology and Obstetrics

GTV:

Gross tumor volume

HDR:

High-dose-rate

HR-CTV:

High-risk clinical target volume

ICBT:

Intracavitary brachytherapy

ISBT:

Interstitial brachytherapy

OARs:

Organs at risk

RALS:

Remote afterloading system

RT:

Radiation therapy

References

  1. 1.

    Swift SE. The distribution of pelvic organ support in a population of female subjects seen for routine gynecologic health care. Am J Obstet Gynecol. 2000;183:277–85.

  2. 2.

    Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, Spino C, Whitehead WE, Wu J, Brody DJ. Pelvic Floor Disorders Network. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. 2008;300:1311–6.

  3. 3.

    Slieker-ten Hove MC, Pool-Goudzwaard AL, Eijkemans MJ, Steegers-Theunissen RP, Burger CW, Vierhout ME. The prevalence of pelvic organ prolapse symptoms and signs and their relation with bladder and bowel disorders in a general female population. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20:1037–45.

  4. 4.

    Ea E, Ra B. Carcinoma of the cervix in association with procidentia. Q Bull Northwest Univ Med Sch. 1950;24(1):12.

  5. 5.

    Daw E. Carcinoma of cervix in association with procidentia. Br J Clin Pract. 1972;26:197–200.

  6. 6.

    da Silva BB, da Costa Araújo R, Filho CP, Melo JA. Carcinoma of the cervix in association with uterine prolapse. Gynecol Oncol. 2002;84:349–50.

  7. 7.

    Matsuo K, Fullerton ME, Moeini A. Treatment patterns and survival outcomes in patients with cervical cancer complicated by complete uterine prolapse: a systematic review of literature. Int Urogynecol J. 2016;27:29–38.

  8. 8.

    Kriplani A, Relan S, Kumar L, Biswal BM, Rath GK. Incarcerated procidentia: a rare complication of carcinoma cervix. Aust N Z J Obstet Gynaecol. 1995;35:463–4.

  9. 9.

    Reimer D, Sztankay A, Steppan I, Abfalter E, Lunzer H, Marth C, Zeimet AG. Cervical cancer associated with genital prolapse--a brief review of the literature and long-term results of successful treatment with radiochemotherapy and surgery in a very frail patient. Eur J Gynaecol Oncol. 2008;29:272–5.

  10. 10.

    Dawkins JC, Lewis GK, Toy EP. Cervical cancer complicating pelvic organ prolapse, and use of a pessary to restore anatomy for optimal radiation: a case report. Gynecol Oncol Rep. 2018;26:14–6.

  11. 11.

    Bump RC, Mattiasson A, Bø K, Brubaker LP, DeLancey JO, Klarskov P, Shull BL, Smith AR. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996;175:10–7.

  12. 12.

    Asherman JG. Traumatic intra-uterine adhesions. J Obstet Gynaecol Br Emp. 1950;57:892–6.

  13. 13.

    Valle RF, Sciarra JJ. Intrauterine adhesions: hysteroscopic diagnosis, classification, treatment, and reproductive outcome. Am J Obstet Gynecol. 1988;158:1459–70.

  14. 14.

    Haie-Meder C, Pötter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, Dumas I, Hellebust TP, Kirisits C, Lang S, Muschitz S, Nevinson J, Nulens A, Petrow P, Wachter-Gerstner N, Gynaecological (GYN) GEC-ESTRO working group. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74:235–45.

  15. 15.

    Pötter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, Dumas I, Erickson B, Lang S, Nulens A, Petrow P, Rownd J, Kirisits C, GEC ESTRO working group. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78:67–77.

  16. 16.

    National Cancer Institute common terminology criteria for adverse events (CTCAE) 4.03. 2010. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.

  17. 17.

    Brennand EA, Banerjee RN. Letter to the editor regarding: “treatment patterns and survival outcomes in patients with cervical cancer complicated by complete uterine prolapse: a systematic review of literature”. Int Urogynecol J. 2016;27:1283.

  18. 18.

    Karateke A, Tugrul S, Yakut Y, Gürbüz A, Cam C. Management of a case of primary vaginal cancer with irreducible massive uterine prolapse--a case report. Eur J Gynaecol Oncol. 2006;27:528–30.

  19. 19.

    Pardal C, Correia C, Serrano P. Carcinoma of the cervix complicating a genital prolapse. BMJ Case Rep. 2015;24:2015.

  20. 20.

    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Version 1.2018 Cervical Cancer. https://www2.tri-kobe.org/nccn/guideline/gynecological/english/cervical.pdf.

  21. 21.

    Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D. The American brachytherapy society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000;48:201–11.

  22. 22.

    Itami J, Hara R, Kozuka T, Yamashita H, Nakajima K, Shibata K, Abe Y, Fuse M, Ito M. Transperineal high-dose-rate interstitial radiation therapy in the management of gynecologic malignancies. Strahlenther Onkol. 2003;179:737–41.

  23. 23.

    Yoshida K, Yamazaki H, Takenaka T, Kotsuma T, Yoshida M, Furuya S, Tanaka E, Uegaki T, Kuriyama K, Matsumoto H, Yamada S, Ban C. A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer. Int J Radiat Oncol Biol Phys. 2010;77:765–72.

  24. 24.

    Saitoh J, Ohno T, Sakurai H, Katoh H, Wakatsuki M, Noda SE, Suzuki Y, Sibuya K, Takahashi T, Nakano T. High-dose-rate interstitial brachytherapy with computed tomography-based treatment planning for patients with locally advanced uterine cervical carcinoma. J Radiat Res. 2011;52:490–5.

  25. 25.

    Dimopoulos JC, Pötter R, Lang S, Fidarova E, Georg P, Dörr W, Kirisits C. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol. 2009;93:311–5.

  26. 26.

    Ohno T, Noda SE, Okonogi N, Murata K, Shibuya K, Kiyohara H, Tamaki T, Ando K, Oike T, Ohkubo Y, Wakatsuki M, Saitoh JI, Nakano T. In-room computed tomography-based brachytherapy for uterine cervical cancer: results of a 5-year retrospective study. J Radiat Res. 2017 Jul 1;58(4):543–51.

Download references

Acknowledgements

We thank Angela Morben, DVM, ELS, from Edanz Group (www.edanzediting.com/ac), for editing a draft of this manuscript.

Funding

None.

Availability of data and materials

The data used during this study are available from the corresponding author on reasonable request.

Author information

NI treated the patient and was a major contributor to writing the manuscript. MAS and KK performed the gynecological examination. TM and MO took part in the treatment. All authors read and approved the final manuscript.

Correspondence to Naoya Ishibashi.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent to publish this case report and accompanying images was obtained from the patient.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Brachytherapy
  • Vaginal cancer
  • Uterine prolapse
  • Intrauterine adhesion